Astellas Pharma Inc.

DB:YPH Stock Report

Market Cap: €15.4b

Astellas Pharma Management

Management criteria checks 2/4

Astellas Pharma's CEO is Naoki Okamura, appointed in Apr 2023, has a tenure of 2.08 years. total yearly compensation is ¥461.00M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth €489.85K. The average tenure of the management team and the board of directors is 4 years and 1.9 years respectively.

Key information

Naoki Okamura

Chief executive officer

JP¥461.0m

Total compensation

CEO salary percentage29.50%
CEO tenure2.1yrs
CEO ownership0.003%
Management average tenure4yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Naoki Okamura's remuneration changed compared to Astellas Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

JP¥51b

Dec 31 2024n/an/a

-JP¥57b

Sep 30 2024n/an/a

JP¥55b

Jun 30 2024n/an/a

JP¥22b

Mar 31 2024JP¥461mJP¥136m

JP¥17b

Dec 31 2023n/an/a

JP¥4b

Sep 30 2023n/an/a

JP¥38b

Jun 30 2023n/an/a

JP¥107b

Mar 31 2023JP¥204mJP¥70m

JP¥99b

Dec 31 2022n/an/a

JP¥136b

Sep 30 2022n/an/a

JP¥149b

Jun 30 2022n/an/a

JP¥118b

Mar 31 2022n/an/a

JP¥124b

Dec 31 2021n/an/a

JP¥120b

Sep 30 2021n/an/a

JP¥119b

Jun 30 2021n/an/a

JP¥101b

Mar 31 2021JP¥236mJP¥70m

JP¥121b

Dec 31 2020n/an/a

JP¥138b

Sep 30 2020n/an/a

JP¥140b

Jun 30 2020n/an/a

JP¥187b

Mar 31 2020JP¥232mJP¥53m

JP¥195b

Compensation vs Market: Naoki's total compensation ($USD3.23M) is below average for companies of similar size in the German market ($USD5.30M).

Compensation vs Earnings: Naoki's compensation has increased by more than 20% in the past year.

CEO

Naoki Okamura (62 yo)

2.1yrs
Tenure
JP¥461,000,000
Compensation

Mr. Naoki Okamura, BSc, served as Chief Business Officer at Astellas Pharma Inc. since September 2021 until 2022. He served as Executive Vice President at Astellas Pharma Inc. since 2021 until April 1, 202...

Leadership Team

NamePositionTenureCompensationOwnership
Naoki Okamura
President2.1yrsJP¥461.00m0.0032%
€ 489.8k
Atsushi Kitamura
Senior Executive Officer & CFO2.3yrsno datano data
Nobue Yasuda
General Manager of Finance & Accounting Departmentno datano datano data
Yoshitsugu Shitaka
Chief Scientific Officer & Senior Managing Executive Officer4.3yrsno datano data
Tatjana Dragovic
General Counselless than a yearno datano data
Katsuyoshi Sugita
Chief People Officer4yrsno data0.00061%
€ 94.0k
Stig Ogata
Vice President of Corporate Communications7.1yrsno datano data
Nobuaki Tanaka
President of Japan Commercial & Senior Corporate Executive8.9yrsno datano data
Jun Kono
Senior Executive Officer & Head of Japan Commercial1.3yrsno datano data
Leticia Delgado-Herrera
VP and Rx+ M&D Head6.3yrsno datano data
Nori Kuwahara
Senior Vice President of Planning & Administrationno datano datano data
Salim Mujais
Senior VP & TA Head of Medical Specialtiesno datano datano data
4.0yrs
Average Tenure

Experienced Management: YPH's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Naoki Okamura
President5.9yrsJP¥461.00m0.0032%
€ 489.8k
Katsuyoshi Sugita
Chief People Officer1.9yrsno data0.00061%
€ 94.0k
Takashi Tanaka
Independent Outside Director3.9yrsno datano data
Masahiro Miyazaki
Outside Independent Director1.9yrsno data0.000060%
€ 9.2k
Kenji Yasukawa
Chairman of the Board7.9yrsJP¥309.00m0.010%
€ 1.5m
Tomoko Aramaki
Outside Independent Directorless than a yearno datano data
Eriko Sakurai
Independent Outside Director2.9yrsno datano data
Mika Nakayama
Independent Outside Director2.9yrsno datano data
Rie Akiyama
Outside Independent Director1.9yrsno datano data
Yoichi Ohno
Outside Independent Director1.9yrsno datano data
Rika Hirota
Directorless than a yearno datano data
1.9yrs
Average Tenure
63yo
Average Age

Experienced Board: YPH's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/24 11:30
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Astellas Pharma Inc. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research